Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

Literature DB >> 3816916

Controlled double blind trial of nisoldipine in the treatment of idiopathic Raynaud's phenomenon.

T Gjørup, O J Hartling, H Kelbaek, S L Nielsen.

Abstract

In a controlled double blind trial the symptomatic effect of the calcium channel blocker nisoldipine was assessed in 19 patients with idiopathic Raynaud's phenomenon. Nisoldipine significantly reduced the frequency of attacks (p less than 0.05), whilst having a non-significant tendency (p less than 0.10) to reduce the severity of attacks. Side-effects were uncommon. It is concluded that nisoldipine is a promising agent for the symptomatic treatment of idiopathic Raynaud's phenomenon.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1986 PMID： 3816916 DOI： 10.1007/bf00613511

Source DB: PubMed Journal: Eur J Clin Pharmacol ISSN： 0031-6970 Impact factor: 2.953

12 in total

1. Controlled double-blind trial of the clinical effect of nifedipine in the treatment of idiopathic Raynaud's phenomenon.

Authors: T Gjørup; H Kelbaek; O J Hartling; S L Nielsen
Journal: Am Heart J Date: 1986-04 Impact factor: 4.749

2. Treatment of digital vasospastic disease with the calcium-entry blocker nifedipine.

Authors: H Nilsson; T Jonasson; I Ringqvist
Journal: Acta Med Scand Date: 1984

3. Pathophysiology of Raynaud's disease.

Authors: J L Halperin; J D Coffman
Journal: Arch Intern Med Date: 1979-01

4. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.

Authors: R J Rodeheffer; J A Rommer; F Wigley; C R Smith
Journal: N Engl J Med Date: 1983-04-14 Impact factor: 91.245

5. Evaluation and management of patients with Raynaud's syndrome.

Authors: J M Porter; S P Rivers; C J Anderson; G M Baur
Journal: Am J Surg Date: 1981-08 Impact factor: 2.565

6. Prevalence of primary Raynaud phenomena in young females.

Authors: N Olsen; S L Nielsen
Journal: Scand J Clin Lab Invest Date: 1978-12 Impact factor: 1.713

7. Nifedipine-induced fingertip vasodilation in patients with Raynaud's phenomenon.

Authors: M A Creager; K M Pariser; E M Winston; H M Rasmussen; K B Miller; J D Coffman
Journal: Am Heart J Date: 1984-08 Impact factor: 4.749

8. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.

Authors: C D Smith; R J McKendry
Journal: Lancet Date: 1982-12-11 Impact factor: 79.321

Review 9. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part I: Basic and clinical electrophysiologic effects.

Authors: E M Antman; P H Stone; J E Muller; E Braunwald
Journal: Ann Intern Med Date: 1980-12 Impact factor: 25.391

10. Nifedipine as a therapeutic modality for Raynaud's phenomenon.

Authors: E L Winston; K M Pariser; K B Miller; D N Salem; M A Creager
Journal: Arthritis Rheum Date: 1983-10

8 in total

1. The effects of stress, anxiety, and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study.

Authors: K M Brown; S J Middaugh; J A Haythornthwaite; L Bielory
Journal: J Behav Med Date: 2001-04

Review 2. Pathogenesis and treatment of Raynaud's phenomenon.

Authors: J D Coffman
Journal: Cardiovasc Drugs Ther Date: 1990-01 Impact factor: 3.727

Review 3. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors: H A Friedel; E M Sorkin
Journal: Drugs Date: 1988-12 Impact factor: 9.546